|
1
|
Jemal A, Thomas A, Murray T and Thun M:
Cancer statistics. CA Cancer J Clin. 52:23–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertone-Johnson ER: Epidemiology of
ovarian cancer: a status report. Lancet. 365:101–102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bell DA: Origins and molecular pathology
of ovarian cancer. Mod Pathol. 18(Suppl 2): S19–S32. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sood AK and Buller RE: Drug resistance in
ovarian cancer: from the laboratory to the clinic. Obstet Gynecol.
92:312–319. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuire WP, Hoskins WJ, Brady MF, et al:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mattick JS: The genetic signatures of
noncoding RNAs. PLoS Genet. 5:e10004592009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yasuda J and Hayashizaki Y: The RNA
continent. Adv Cancer Res. 99:77–112. 2008.
|
|
9
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gupta RA, Shah N, Wang KC, Kim J, et al:
Long non-coding RNA HOTAIR reprograms chromatin state to promote
cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Z, Zhou L, Wu LM, et al:
Overexpression of long non-coding RNA HOTAIR predicts tumor
recurrence in hepato-cellular carcinoma patients following liver
transplantation. Ann Surg Oncol. 18:1243–1250. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kogo R, Shimamura T, Mimori K, Kawahara K,
et al: Long noncoding RNA HOTAIR regulates polycomb-dependent
chromatin modification and is associated with poor prognosis in
colorectal cancers. Cancer Res. 71:6320–6326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim K, Jutooru I, Chadalapaka G, et al:
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic
activity in pancreatic cancer. Oncogene. 32:1616–1625. 2013.
View Article : Google Scholar
|
|
14
|
Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and
De W: The long non-coding RNA HOTAIR indicates a poor prognosis and
promotes metastasis in non-small cell lung cancer. BMC Cancer.
13:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rinn JL, Kertesz M, Wang JK, Squazzo SL,
Xu X, et al: Functional demarcation of active and silent chromatin
domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gadducci A, Cosio S, Zola P, et al:
Surveillance procedures for patients treated for epithelial ovarian
cancer: a review of the literature. Int J Gynecol Cancer. 17:21–31.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Godwin AK, Meister A, O’Dwyer PJ, Huang
CS, Hamilton TC and Anderson ME: High resistance to cisplatin in
human ovarian cancer cell lines is associated with marked increase
of glutathione synthesis. Proc Natl Acad Sci USA. 89:3070–3074.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kelley SL, Basu A, Teicher BA, Hacker MP,
Hamer DH and Lazo J: Overexpression of metallothionein confers
resistance to anticancer drugs. Science. 241:1813–1815. 1998.
View Article : Google Scholar
|
|
19
|
Parker RJ, Eastman A, Bostick-Bruton F and
Reed E: Acquired cisplatin resistance in human ovarian cancer cells
is associated with enhanced repair of cisplatin-DNA lesions and
reduced drug accumulation. J Clin Invest. 87:772–777. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stordal BK, Davey MW and Davey RA:
Oxaliplatin induces drug resistance more rapidly than cisplatin in
H69 small cell lung cancer cells. Cancer Chemother Pharmacol.
58:256–265. 2006. View Article : Google Scholar
|
|
21
|
Pardal R, Clarke MF and Morrison SJ:
Applying the principles of stem-cell biology to cancer. Nat Rev
Cancer. 3:895–902. 2003. View
Article : Google Scholar
|
|
22
|
Curley MD, Garrett LA, Schorge JO, Foster
R and Rueda BR: Evidence for cancer stem cells contributing to the
pathogenesis of ovarian cancer. Front Biosci (Landmark Ed).
16:368–392. 2011. View
Article : Google Scholar
|
|
23
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et
al: Glioma stem cells promote radioresistance by preferential
activation of the DNA damage response. Nature. 7:444756–760.
2006.
|
|
24
|
Neuzil J, Stantic M, Zobalova R, Chladova
J, Wang X, et al: Tumour-initiating cells vs. cancer ‘stem’ cells
and CD133: what’s in the name? Biochem Biophys Res Commun.
355:855–859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pasini D, Bracken AP, Hansen JB, Capillo M
and Helin K: The polycomb group protein Suz12 is required for
embryonic stem cell differentiation. Mol Cell Biol. 27:3769–3779.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen YH, Hung MC and Li LY: EZH2: a
pivotal regulator for controlling cell differentiation. Am J Transl
Res. 4:364–375. 2012.
|
|
27
|
Khalil AM, Guttman M, Huarte M, Garber M,
et al: Many human large intergenic noncoding RNAs associate with
chromatin-modifying complexes and affect gene expression. Proc Natl
Acad Sci USA. 106:11667–11672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pádua Alves C, Fonseca AS, Muys BR, et al:
Brief report: The lincRNA Hotair is required for
epithelial-to-mesenchymal transition and stemness maintenance of
cancer cells lines. Stem Cells. 31:2827–2832. 2013. View Article : Google Scholar
|
